These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 38732027)

  • 1. Antisense Oligonucleotides (ASOs) in Motor Neuron Diseases: A Road to Cure in Light and Shade.
    Cantara S; Simoncelli G; Ricci C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nusinersen in the Treatment of Spinal Muscular Atrophy.
    Goodkey K; Aslesh T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():69-76. PubMed ID: 30171535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of Cell-Penetrating Peptide-Conjugated Antisense Oligonucleotides for the Treatment of SMA.
    Leckie J; Yokota T
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gene Therapies in Motor Neuron Diseases ALS and SMA].
    Günther R
    Fortschr Neurol Psychiatr; 2023 Apr; 91(4):153-163. PubMed ID: 36822211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense Oligonucleotides for the Study and Treatment of ALS.
    Boros BD; Schoch KM; Kreple CJ; Miller TM
    Neurotherapeutics; 2022 Jul; 19(4):1145-1158. PubMed ID: 35653060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed
    Wijaya YOS; Niba ETE; Nishio H; Okamoto K; Awano H; Saito T; Takeshima Y; Shinohara M
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives.
    Lejman J; Panuciak K; Nowicka E; Mastalerczyk A; Wojciechowska K; Lejman M
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage inclusions in cerebrospinal fluid following treatment initiation with antisense oligonucleotide therapies in motor neuron diseases.
    Vidovic M; Menschikowski M; Freigang M; Lapp HS; Günther R
    Neurol Res Pract; 2024 Feb; 6(1):11. PubMed ID: 38383503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
    Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
    Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic architecture of motor neuron diseases.
    Chaudhary R; Agarwal V; Rehman M; Kaushik AS; Mishra V
    J Neurol Sci; 2022 Mar; 434():120099. PubMed ID: 34965490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sense of antisense therapies in ALS.
    Van Daele SH; Masrori P; Van Damme P; Van Den Bosch L
    Trends Mol Med; 2024 Mar; 30(3):252-262. PubMed ID: 38216448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy.
    Cappella M; Pradat PF; Querin G; Biferi MG
    J Neuromuscul Dis; 2021; 8(1):25-38. PubMed ID: 33074186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A; Rombo R; Janzen E; Ling KK; Hupperich K; Rigo F; Bennett CF; Wirth B
    Neurobiol Dis; 2022 Sep; 171():105795. PubMed ID: 35724821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.
    Hammond SM; Abendroth F; Gait MJ; Wood MJA
    Methods Mol Biol; 2019; 2036():221-236. PubMed ID: 31410800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
    Singh NN; Lee BM; DiDonato CJ; Singh RN
    Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis.
    Ly CV; Miller TM
    Curr Opin Neurol; 2018 Oct; 31(5):648-654. PubMed ID: 30028737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders.
    Hill SF; Meisler MH
    Dev Neurosci; 2021; 43(3-4):247-252. PubMed ID: 34412058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
    Paton DM
    Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.
    Li Q
    Yonsei Med J; 2020 Apr; 61(4):273-283. PubMed ID: 32233169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.